Hepatocellular Carcinoma: 2018 Global Pipeline Review, H1 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Hepatocellular Carcinoma - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 18, 76, 60, 1, 3, 92, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 10, 6, 1, 1, 25 and 1 molecules, respectively.

Companies Mentioned

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Eureka Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Galaxy Biotech LLC
  • GC Pharma
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • InteRNA Technologies BV
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • Merck KGaA
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Nymox Pharmaceutical Corp
  • Omeros Corp
  • Oncolys BioPharma Inc
  • Oncolytics Biotech Inc
  • Oneness Biotech Co Ltd
  • Ono Pharmaceutical Co Ltd
  • Oxford BioTherapeutics Ltd
  • PepVax Inc
  • Pfizer Inc
  • Takeda Pharmaceutical Co Ltd

Key Topics Covered

  1. Introduction
  2. Hepatocellular Carcinoma - Overview
  3. Hepatocellular Carcinoma - Therapeutics Development
  4. Hepatocellular Carcinoma - Therapeutics Assessment
  5. Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
  6. Hepatocellular Carcinoma - Drug Profiles
  7. Hepatocellular Carcinoma - Dormant Projects
  8. Hepatocellular Carcinoma - Discontinued Products
  9. Hepatocellular Carcinoma - Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/fbqdpq/hepatocellular?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs